This medication is applied in clinical settings that involve acute or unstable symptom patterns, used specifically to provide symptomatic relief for conditions involving episodic or fluctuating manifestations of Angina Pectoris. It is commonly used across conditions presenting with acute episodes linked to Coronary Artery Disease. The medication helps address symptom clusters that create noticeable physiological strain, such as chest pain, tightness, or squeezing.

Cafinitrina is relevant across domains where additional symptomatic support is needed, commonly used in conditions characterized by periods of heightened symptoms. It is applied in scenarios where symptoms cluster into patterns requiring short-term supportive management, relevant both for managing symptoms that become more disruptive during flare-ups and for situational supportive management relevant in contexts involving heightened systemic burden such as expected physical or emotional tension.

“This medication is used in areas where short-term symptom management is appropriate for symptoms linked to organ-specific functional stress, and its purpose is to provide symptomatic relief when symptoms become more noticeable.”

The main indications are the management of Angina Pectoris and providing situational supportive management to patients with Coronary Artery Disease. This approach supports general well-being during symptomatic phases and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Support for Symptomatic Discomfort The medicine is generally applied when short-term symptomatic assistance is needed for chest discomfort, and is used for managing symptom clusters that may appear suddenly or fluctuate.

Regulatory References

1. NIH MedlinePlus Drug Information

The official eligibility profile for Cafinitrina is defined by clear regulatory constraints outlining which patient groups may use the medicine and which are strictly excluded based on authoritative government labeling.

Eligibility Scope

Absolute Contraindications (Must Not Use):

• Patients with Severe Anemia or existing conditions that cause Increased Intracranial Pressure (such as head trauma).
• Patients experiencing Acute Circulatory Failure or Shock.
• Patients with known hypersensitivity to any component, including nitroglycerin or caffeine.
• Concomitant use with Phosphodiesterase type 5 (PDE-5) Inhibitors (e.g., sildenafil) or sGC Stimulators (e.g., riociguat) is strictly prohibited.

Conditional and Restricted Use:

• Use requires careful monitoring in patients with Acute Myocardial Infarction or Acute Heart Failure.
• The medicine is not established and not recommended for the pediatric population.
• Older Adults may require dose adjustments due to a higher likelihood of age-related organ impairment.
• For pregnancy and lactation, a physician must determine the benefit-risk ratio, as it is unknown if the drug is excreted in human milk.

Eligibility Classifications

Regulatory labeling establishes absolute ineligibility through contraindication for certain severe cardiovascular and neurological conditions. It classifies pediatric use as not established and defines specific patient groups, such as those with existing hypotension or acute cardiac conditions, as requiring conditional use under close clinical oversight.

The official interaction profile for the components of Cafinitrina—Nitroglycerin and Caffeine—is defined by documented risks of severe blood pressure changes and altered systemic drug exposure.

Contraindicated Combinations (Nitroglycerin Component)

Co-administration with specific medicinal products is formally prohibited due to the risk of severe, life-threatening hypotension (dangerously low blood pressure):

• Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil). These compounds potentiate the hypotensive effect of organic nitrates.
• Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat). Concomitant use can cause profound hypotension.

Documented Pharmacodynamic and Exposure Interactions

• Ergot Derivatives: Sublingual nitroglycerin may increase the systemic exposure of oral ergot derivatives by decreasing their first-pass metabolism, which can increase the risk of ergotism.
• Alcohol: Use with alcohol may result in additive hypotensive effects, specifically marked orthostatic hypotension (a drop in blood pressure upon standing).
• Antihypertensive Agents: The nitroglycerin component may cause enhanced hypotensive effects when co-administered with other blood pressure-lowering medications, including beta-blockers and calcium channel blockers.
• Caffeine Sources: Patients are advised to limit concurrent intake of excessive dietary caffeine (e.g., certain beverages or supplements) to avoid additive CNS stimulant effects, such as increased nervousness or heart rate.

The mechanism of action for Cafinitrina is defined by two mechanistically distinct, complementary physiological domains: the direct modulation of vascular tone and the alteration of central nervous system (CNS) function. The vasodilatory action begins as Nitroglycerin is converted to Nitric Oxide (NO) in vascular smooth muscle, activating the enzyme soluble guanylate cyclase (sGC). This initiates the NO-cGMP signaling cascade , which causes smooth muscle relaxation and vessel widening. This physiological consequence involves a reduction in the volume of blood returning to the heart (preload) and the resistance the heart pumps against (afterload), thus lowering the heart muscle's oxygen demand and modulating the myocardial workload. The second component, Caffeine, acts primarily in the CNS as a non-selective competitive antagonist of adenosine receptors (A1 and A2A). By blocking these inhibitory receptors, the drug modulates neurobehavioral activity, resulting in increased neuronal activity and psychomotor stimulation. This interaction establishes a complementary systemic effect profile. However, this vascular mechanism is constrained by nitrate tolerance (tachyphylaxis), where repeated exposure can reduce the efficiency of the NO-cGMP pathway.

Cafinitrina is designated for administration via the sublingual route as a combination tablet containing 1 mg of Nitroglycerin and 25 mg of Caffeine Citrate. This route is essential for rapid absorption, and the usage is defined for both immediate intervention and situational prevention.

Administration for Acute Symptoms

For the treatment of acute episodes, the regimen begins with taking one (1) tablet at the first sign of discomfort. If the initial administration does not achieve the expected effect, the intake may be repeated up to four (4) additional times, administered at short intervals of 10 minutes between doses. This defines the maximum short-term use pattern.

Preparation and Contextual Use

Instructions for taking this specific sublingual tablet require the user to place the tablet in the mouth, chew it immediately without swallowing, and then place the resulting mass under the tongue to dissolve. This unique preparation method is necessary for proper drug absorption.

For situational prophylactic use, the administration involves taking one (1) tablet 5 to 10 minutes before engaging in any activity known to trigger symptoms. The overall use pattern is short-term and intermittent. Furthermore, the combination product is not recommended for use in children and adolescents, as routine pediatric regimens are not established.

Cafinitrina: Research Evidence Overview

Evidence for Use in Acute Angina and Episodic Symptoms

Researchers utilized short-term Randomized Controlled Trials (RCTs) and crossover study designs to observe how symptoms change over time in specific patient groups. These studies primarily included adult patients with stable Coronary Artery Disease (CAD) or Angina Pectoris, which are conditions characterized by episodic manifestations. Studies monitored patient-reported outcomes describing perceived discomfort.

The evidence derived from these settings describes group patterns and focuses on episodes where symptoms become more noticeable, examining outcomes related to episodic or acute changes. Research describes how quickly symptoms evolved in the observed populations during the defined time intervals. Findings contribute to the broader evidence landscape, but this research does not determine whether an individual will respond similarly.

Research Focus: Symptom Measurement and Functional Capacity

Trials monitored outcomes reflecting daily functioning or activity level, such as total time a patient could comfortably exercise during a stress test before symptoms appeared. Studies monitored the relationship between these functional measurements and defined time intervals. These studies help show what has been observed so far regarding both subjective experience and functional measurements.

The Research Context of the Combination Product

This medicine is a fixed combination of two active components. While the primary component, Nitroglycerin, was studied extensively, comparative evidence is lacking for the specific combination with Caffeine. Data are still emerging on what contribution the secondary component (Caffeine) provides to this specific formulation. Subgroup findings regarding this combination are uncertain, and research is ongoing to fully characterize the research scenario.

Key Limitations and Ongoing Research Uncertainty

The research exploring short-term symptom changes generally involved follow-up durations that were limited. This means that long-term effects are not fully established, and the durability of the observed response was not fully characterized in the studies. The body of research primarily relates to stable adult patients studied, and data for certain groups, such as older adults or those with comorbidities, remain insufficient.

Key Studies & References

1. Label: NITROSTAT- nitroglycerin tablet (Official FDA Label/DailyMed)

Common questions about Cafinitrina (FAQ)

Q: How does Cafinitrina differ from other common medicines for the same condition?

Official information describes this medicine as a unique fixed combination of two active components. These are a potent vasodilator, Nitroglycerin, and a central nervous system stimulant, Caffeine. The inclusion of these two distinct components defines its specific pharmacological approach.

Q: Do many people take Cafinitrina for a long time?

Regulatory documentation categorizes the overall use pattern for this medicine as short-term and intermittent. Furthermore, official research reviews indicate that the long-term effects for this specific medicine are not fully established.

Q: How long does it usually take to feel the effects of Cafinitrina?

The medicine is designed for rapid action by being administered via the sublingual route, meaning it dissolves under the tongue. This route is officially described as resulting in a fast onset of action suitable for situations demanding a swift response.

Q: Can Cafinitrina cause drowsiness or affect my ability to drive?

Regulatory safety information lists dizziness and drowsiness as common adverse reactions. The presence of these effects may be associated with reduced ability to operate machinery or drive.

Q: What are the most commonly reported side effects of Cafinitrina?

Regulatory documentation indicates that headache is a very common adverse reaction, reported in ge 1 in 10 patients. Common reactions, affecting up to 1 in 10 patients, include dizziness, drowsiness, fast heart rate, low blood pressure, and fatigue.

Q: Is the efficacy of Cafinitrina supported by long-term follow-up studies?

Official research overviews state that follow-up durations in the studies conducted were generally limited. This means that the durability and long-term effects of the observed response are not fully characterized.

Q: Can children take Cafinitrina, and is the evidence strong for this group?

Regulatory labeling states that this medicine is not established and not recommended for the pediatric population. This is because routine pediatric regimens and specific evidence for this age group are not established.

Q: What kind of studies support the use of Cafinitrina?

The supporting research involves short-term Randomized Controlled Trials (RCTs) and crossover study designs. These trials primarily included adult patients diagnosed with stable Coronary Artery Disease or Angina Pectoris.

Q: Why are official sources cautious about Cafinitrina and pregnancy?

Official sources state that for both pregnancy and lactation, a physician must determine the benefit-risk ratio. This caution is due to the fact that it is unknown if the drug is excreted in human milk.

Q: How do researchers measure the 'success' of Cafinitrina in studies?

Trials monitored outcomes reflecting functional capacity and patient experience. This included patient-reported outcomes describing perceived discomfort and the total time a patient could comfortably exercise during stress tests before symptoms appeared.

Q: Is the medication considered a 'cure' for the condition it treats?

The general purpose of the medicine is officially described as rapidly restoring the balance between the heart muscle’s oxygen supply and demand. Its role is to provide prompt relief associated with compromised coronary blood flow, not to serve as a cure for the underlying condition.

Q: If I miss a dose of Cafinitrina, what is the general guidance?

Standard regulatory documents typically contain specific instructions for what action to take if a scheduled dose is missed. This guidance is usually provided within the detailed instructions for use.

Q: Can taking Cafinitrina affect the results of lab tests?

Official product information must be consulted for any known effects on laboratory test results or interactions that may interfere with testing procedures.

Q: What happens if I stop taking Cafinitrina suddenly?

Safety information indicates that abruptly stopping treatment is associated with a possible risk of withdrawal or a rebound effect. This effect is described as potentially precipitating angina or myocardial infarction.

Q: Is Cafinitrina recommended for people with kidney problems?

Official guidance for the Nitroglycerin component indicates that it can be used in patients with renal impairment. This is because there is no significant risk of accumulation in these patients.

Q: Does Cafinitrina make people gain or lose weight?

Official regulatory documentation that lists adverse reactions does not include weight gain or loss among the reported side effects for this medicine.

Q: Is it known if the effects of Cafinitrina lessen over time?

Official documentation describes the vascular mechanism. This mechanism is linked to a concept called nitrate tolerance (tachyphylaxis), where repeated exposure may cause a reduction in the drug's effectiveness over time.

Q: Are there specific symptoms that require immediate medical attention while on Cafinitrina?

Regulatory safety information documents serious adverse reactions. These include the worsening of angina pectoris, circulatory failure, or severe skin reactions, such as exfoliative dermatitis.

Q: What does the term 'contraindication' mean in relation to Cafinitrina?

In the context of this medicine, a contraindication refers to absolute ineligibility. It signifies a condition or circumstance where the medication must not be used due to a serious risk of harm, as established by regulatory labeling.

Q: What is the general patient expectation for feeling better after starting the drug?

The medicine is officially defined by its ability to rapidly influence the circulatory system and lessen the heart’s workload. Its intended purpose is to provide prompt relief associated with compromised coronary blood flow.

Q: If Cafinitrina interacts with alcohol, what does 'interacts' mean in this context?

The official interaction profile states that use with alcohol may result in additive hypotensive effects. This specifically refers to orthostatic hypotension, which is a sudden drop in blood pressure when changing posture, such as standing up.

Q: Why do some people report feeling lightheaded after starting Cafinitrina?

Official regulatory documents list both dizziness and low blood pressure as common adverse reactions for this medicine. These effects on the circulatory and nervous systems can contribute to feelings of lightheadedness.

Q: How quickly does Cafinitrina leave the body?

Pharmacokinetic studies for the Nitroglycerin component show that it has a very short terminal half-life. This means the active drug quickly leaves the bloodstream, typically in the range of a few minutes.

Q: Why is Cafinitrina not recommended for people with a history of heart issues?

Official documentation requires careful medical monitoring for patients with recent myocardial infarction or acute heart failure. This is due to the nature of the drug’s potent effects on the cardiovascular system.

Q: Are there specific patient groups where Cafinitrina is studied less?

The body of regulatory research primarily relates to stable adult patients who were studied in clinical trials. Data for certain groups, such as older adults or those with multiple existing health conditions (comorbidities), remain insufficient.

Q: Are there any major diet restrictions associated with Cafinitrina?

Official documentation advises limiting the concurrent intake of excessive dietary caffeine. Additionally, the label warns that alcohol use may result in additive hypotensive effects, which is a significant safety consideration.

Q: Do I need to take Cafinitrina with food?

Regulatory instructions specify a unique sublingual administration method where the tablet is chewed and dissolved under the tongue. Since the drug is absorbed directly into the bloodstream this way, this specific method of use does not require consumption with food.

Q: What does it mean if an official document lists a 'severe' side effect for Cafinitrina?

Officially listed serious adverse reactions are rare or uncommon but are included in safety documentation due to their clinical significance. Documented examples include the worsening of angina pectoris, circulatory failure, and severe skin reactions like exfoliative dermatitis.

Q: What is the typical timeframe for someone to be on Cafinitrina treatment?

The overall use pattern for this medicine is officially categorized as short-term and intermittent. It is intended for use during immediate intervention or for situational prophylactic use before activity known to trigger symptoms.

Q: Why is Cafinitrina only available by prescription?

The medicine's regulatory status as a prescription-only product is based on its significant pharmacological activity and defined risk profile. This includes the need for individual patient monitoring and the potential for severe adverse reactions and life-threatening drug interactions.

How to Store and Dispose of Cafinitrina

The official labeling mandates strict storage conditions to maintain the potency of Cafinitrina (Nitroglycerin/Caffeine sublingual tablets).

Storage Requirements

The medication must be stored at Controlled Room Temperature, typically 20 C to 25 C. The tablets must be kept in their original container, which must be tightly closed immediately after each use, as failure to do so can cause rapid loss of potency. The container must be protected from light and moisture. The product must not be stored in humid areas like bathrooms or exposed to extreme heat or cold, and should never be frozen.

Disposal Instructions

Cafinitrina must be kept out of the sight and reach of children and pets. Unused or expired medication should be safely discarded, and it is prohibited to flush the tablets down a toilet or pour them down a drain unless specifically instructed by local regulation. Consult a pharmacist for proper disposal methods, such as utilizing a drug take-back program.